Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics has informed BSE that its Board of Directors will meet on February 10, 2026. The main agenda is to consider and approve the Un-Audited Standalone Financial Results along with the Limited Review Report for the quarter and nine months ended December 31, 2025. The company will also discuss other常规 business matters. The meeting notice will also be uploaded on the company's website as required by listing rules.
This is a routine regulatory disclosure ahead of the Q3 FY26 earnings announcement. Investors should watch for the actual results to be published on or after February 10, 2026, which will provide insights into the company's quarterly performance.